title: Drug targets evolve, and so should the methods.
abstract: Design of specific kinase inhibitors is an appealing approach for developing new anticancer treatments. However, only a few success stories have been reported to date. Here we demonstrate how the combination of old-fashioned and new biophysical tools together with recent advances in genomics and molecular evolution can aid in overcoming existing limitations.
authors.affiliation: Howard Hughes Medical Institute, Department of Biochemistry, Brandeis University , Waltham, MA, USA .
authors.forename: Christopher
authors.initials: C
authors.lastname: Wilson
authors.affiliation: Howard Hughes Medical Institute, Department of Biochemistry, Brandeis University , Waltham, MA, USA .
authors.forename: Roman V
authors.initials: RV
authors.lastname: Agafonov
authors.affiliation: Howard Hughes Medical Institute, Department of Biochemistry, Brandeis University , Waltham, MA, USA .
authors.forename: Dorothee
authors.initials: D
authors.lastname: Kern
keywords: Cancer drugs; Gleevec; drug design; evolution; protein kinases